| Pharmaceutical Information |
| Drug Name |
Testolactone |
| Drug ID |
BADD_D02169 |
| Description |
An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer. |
| Indications and Usage |
For palliative treatment of advanced breast cancer in postmenopausal women. |
| Marketing Status |
Discontinued |
| ATC Code |
Not Available |
| DrugBank ID |
DB00894
|
| KEGG ID |
D00153
|
| MeSH ID |
D013738
|
| PubChem ID |
13769
|
| TTD Drug ID |
D0C7JF
|
| NDC Product Code |
Not Available |
| Synonyms |
Testolactone | 1-Dehydrotestolactone | 1 Dehydrotestolactone | delta(1)-Testolactone | Teslac |
|
| Chemical Information |
| Molecular Formula |
C19H24O3 |
| CAS Registry Number |
968-93-4 |
| SMILES |
CC12CCC3C(C1CCC(=O)O2)CCC4=CC(=O)C=CC34C |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
